- Home
- FEMY vs ALGS Comparison
FEMY vs ALGS Comparison
Compare FEMY & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- ALGS
- Stock Information
- Founded
- FEMY 2004
- ALGS 2018
- Country
- FEMY United States
- ALGS United States
- Employees
- FEMY N/A
- ALGS N/A
- Industry
- FEMY Medical/Dental Instruments
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- ALGS Health Care
- Exchange
- FEMY Nasdaq
- ALGS Nasdaq
- Market Cap
- FEMY 31.9M
- ALGS 50.4M
- IPO Year
- FEMY 2021
- ALGS 2020
- Fundamental
- Price
- FEMY $0.93
- ALGS $8.50
- Analyst Decision
- FEMY Strong Buy
- ALGS Strong Buy
- Analyst Count
- FEMY 3
- ALGS 1
- Target Price
- FEMY $8.67
- ALGS $70.00
- AVG Volume (30 Days)
- FEMY 267.9K
- ALGS 94.1K
- Earning Date
- FEMY 08-07-2025
- ALGS 08-05-2025
- Dividend Yield
- FEMY N/A
- ALGS N/A
- EPS Growth
- FEMY N/A
- ALGS N/A
- EPS
- FEMY N/A
- ALGS N/A
- Revenue
- FEMY $1,699,232.00
- ALGS $3,270,000.00
- Revenue This Year
- FEMY $231.84
- ALGS N/A
- Revenue Next Year
- FEMY $245.28
- ALGS $51.55
- P/E Ratio
- FEMY N/A
- ALGS N/A
- Revenue Growth
- FEMY 61.97
- ALGS N/A
- 52 Week Low
- FEMY $0.69
- ALGS $3.76
- 52 Week High
- FEMY $1.80
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- FEMY 48.65
- ALGS 58.69
- Support Level
- FEMY $0.90
- ALGS $8.13
- Resistance Level
- FEMY $0.99
- ALGS $9.10
- Average True Range (ATR)
- FEMY 0.06
- ALGS 0.67
- MACD
- FEMY 0.00
- ALGS 0.06
- Stochastic Oscillator
- FEMY 23.86
- ALGS 73.64
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.